124 related articles for article (PubMed ID: 9722577)
1. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.
Li Q; Gardner K; Zhang L; Tsang B; Bostick-Bruton F; Reed E
J Biol Chem; 1998 Sep; 273(36):23419-25. PubMed ID: 9722577
[TBL] [Abstract][Full Text] [Related]
2. Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.
Li Q; Zhang L; Tsang B; Gardner K; Bostick-Bruton F; Reed E
Cell Mol Life Sci; 1999 Mar; 55(3):456-66. PubMed ID: 10228559
[TBL] [Abstract][Full Text] [Related]
3. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells.
Li Q; Tsang B; Bostick-Bruton F; Reed E
Biochem Pharmacol; 1999 Feb; 57(4):347-53. PubMed ID: 9933022
[TBL] [Abstract][Full Text] [Related]
4. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
[TBL] [Abstract][Full Text] [Related]
5. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
Li Q; Bostick-Bruton F; Reed E
Anticancer Res; 1998; 18(4A):2283-7. PubMed ID: 9703867
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.
Li Q; Ding L; Yu JJ; Mu C; Tsang B; Bostick-Bruton F; Reed E
Int J Oncol; 1998 Nov; 13(5):987-92. PubMed ID: 9772291
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Li QQ; Ding L; Reed E
Res Commun Mol Pathol Pharmacol; 2000; 107(5-6):387-96. PubMed ID: 11589365
[TBL] [Abstract][Full Text] [Related]
10. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
11. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.
Li QQ; Lee RX; Liang H; Wang G; Li JM; Zhong Y; Reed E
Int J Oncol; 2013 Sep; 43(3):721-8. PubMed ID: 23817665
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
13. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
14. SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair.
Zhong X; Li QQ; Reed E
Cell Mol Life Sci; 2003 Apr; 60(4):794-802. PubMed ID: 12785726
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract][Full Text] [Related]
16. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
Hector S; Nava ME; Clark K; Murphy M; Pendyala L
Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Mimnaugh EG; Yunmbam MK; Li Q; Bonvini P; Hwang SG; Trepel J; Reed E; Neckers L
Biochem Pharmacol; 2000 Nov; 60(9):1343-54. PubMed ID: 11008128
[TBL] [Abstract][Full Text] [Related]
20. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.
Daschner PJ; Ciolino HP; Plouzek CA; Yeh GC
Breast Cancer Res Treat; 1999 Feb; 53(3):229-40. PubMed ID: 10369069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
